FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
houre nor roenoneo:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fry Stephen F					2. Issuer Name and Ticker or Trading Symbol ELI LILLY & Co [LLY]									onship of Reportir Il applicable) Director Officer (give til	,	10% Ow	ner pecify below)	
(Last) (First) (Middle) LILLY CORPORATE CENTER						3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								SVP, HR & Diversity				
(Street) INDIANAPOLIS	IN	46	285	4	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individ	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zi _l	0)															
			Table I -	Non-D	erivativ	e Secui	rities Acc	quired, I	Disp	osed of	, or Be	neficially	Owned					
Da Tillo di Godani, (moli o)			Date	nsaction th/Day/Yea	Execu	2A. Deemed Execution Date, if any		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Dispo (D) (Instr. 3, 4 and 5)		sposed Of	5. Amount of Sec Beneficially Own Following Report	ed Dir	Ownership Form: rect (D) or direct (I) (Instr. 4)	7. Nature of Indirect Beneficial				
						(Month	(Month/Day/Year)		v	Amount	t (A) or (D)		Price	Transaction(s) (In and 4)	nstr. 3		Ownership (Instr. 4)	
Common Stock				02/	02/01/2021			M		15,078		A	\$0	115,289		D		
Common Stock			02/	/01/2021			F		6,7	46	D	\$207.97	108,543	·	D			
Common Stock													178		I	401(k)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (In		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Se Underlying Derivative Sec 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	Ownership Form: Direct	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisal		xpiration ate	Title		Amount or Number of Shares	unt or Reported ber of Transaction(s)		[` ′		
Restricted Stock Unit	(1)	02/01/2021		M			15,078	02/01/2021 02/01/2021 C		Com	mon Stock	15,078	\$0	0	D			

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

Remarks:

<u>Crystal T. Williams for Stephen F. Fry, authorization on file</u>

** Signature of Reporting Person

02/03/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Stephen F. Fry Lilly Corporate Center Indianapolis, Indiana 46285

Securities and Exchange Commission Washington, D.C. 20549

Authorization Regarding Reporting Forms

I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms 3, 4, and 5(including any amenda

Anat Hakim, Lilly Corporate Center, Indianapolis, Indiana

Crystal T. Williams, Lilly Corporate Center, Indianapolis, Indiana

Erin Conway, Lilly Corporate Center, Indianapolis, Indiana

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to the Commission.

Date: December 1, 2020

/s/ Stephen F. Fry